Navigation Links
Golden age of prostate cancer treatment hailed as fourth drug in 2 years extends life
Date:8/15/2012

The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life.

A study in the New England Journal of Medicine today shows the drug enzalutamide can significantly extend life and improve quality of life in men with advanced prostate cancer in findings that could further widen the treatment options for men with the disease.

The Institute of Cancer Research, London, and its partner hospital The Royal Marsden NHS Foundation Trust jointly led the new Phase III trial of enzalutamide and the Phase III trials of two other drugs, cabazitaxel and abiraterone. Abiraterone was also discovered at The Institute of Cancer Research and was recently made available on the NHS. A further drug sipuleucel-T has also been shown to extend life in the two-year period.

Professor Alan Ashworth, chief executive of The Institute of Cancer Research (ICR), said cancer research in the UK was finally delivering new treatment options for men with advanced prostate cancer after a long period where the options were limited.

Professor Ashworth said: "Advanced prostate cancer is extremely difficult to treat, and it's taken a massive coordinated effort to finally bring new drugs into the pipeline, after decades where there were no options once old-style hormone treatment stopped working.

"What we're seeing now is an unprecedented period of success for prostate cancer research, with four new drugs shown to extend life in major clinical trials in just two years, and several others showing promise. It truly is a golden age for prostate cancer drug discovery and development."

Professor Martin Gore, medical director of The Royal Marsden Hospital, said: "We are delighted with the recent progress that has been made in the treatment of advanced prostate cancer and to see the impact this is having on our patients, many of whom are living longer with a better quality of life as the result of these new drugs."

Enzalutamide, a new type of hormone treatment, was assessed in 1,199 patients with metastatic castration-resistant prostate cancer that had previously received chemotherapy, in a multinational, randomised placebo-controlled trial sponsored by pharmaceutical companies Medivation and Astellas.

Median survival with enzalutamide was 18.4 months, compared with 13.6 months for men receiving a placebo. Around 43 per cent of men taking enzalutamide as part of the AFFIRM trial reported an improved quality of life, compared with 18 per cent of men taking a placebo. In November last year, the trial's Independent Data Monitoring Committee recommended that the trial be stopped early and men who received the placebo be offered enzalutamide.

The Phase III trial was jointly led by Professor Johann de Bono, head of the Drug Development Unit at the ICR and The Royal Marsden.


'/>"/>

Contact: Jane Bunce
jane.bunce@icr.ac.uk
44-207-153-5106
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
2. New drug prevents spread of human prostate cancer cells
3. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
4. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
5. Study examines adverse effects among different radiation therapies for prostate cancer
6. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
7. Warren Buffett Has Early Stage Prostate Cancer
8. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
9. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
10. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
11. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger novel ... writer with an active imagination and an enthusiasm for action and adventure stories. ... Wild Bill Hart, who sat looking at the thirty-three notches that lined the edges ...
(Date:3/22/2017)... (PRWEB) , ... March 23, 2017 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... BioPharma Asia Convention, currently taking place at the Suntec Singapore International Exhibition & ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome ... devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused ... almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes effect ...
(Date:3/22/2017)... PA (PRWEB) , ... March 22, 2017 , ... Last ... according to a US Department of Agriculture report. While excess dairy can be ... play a role. Lactose sensitivity is the inability to properly digest lactose, a sugar ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 FinancialBuzz.com News Commentary ... due to the significant development and innovation in EP ... Research, the global electrophysiology market was worth $3.42 billion ... by 2022, with a GAGR of 13.4%. Electrophysiology is ... abnormal heartbeats or arrhythmia. The report indicates that in ...
(Date:3/22/2017)... EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... Canada , today announced two new real-world data analyses ... 65 th Annual Pacific Coast Reproductive Society (PCRS) Meeting ... 24 th .   The results being presented are ... 2009 to December 2015 containing data from 15 fertility clinics ...
(Date:3/22/2017)... March 22, 2017  Levine Cancer Institute today ... unit designed to address lung cancer diagnosis, treatment ... Carolinas. The mobile lung unit is the first-of-its-kind ... and treatment interventions through integrated mobile technology, traditional ... Financial barriers and a lack of public transportation ...
Breaking Medicine Technology: